Aslan Fred was awarded 45,000 Artiva Biotherapeutics shares and 155,000 derivative securities on 2026-09-10. The awards left him with 1,494,765 shares and 155,000 derivative securities, meaning the transactions represented about 3.0% and 100.0% of those respective resulting holdings, giving investors updated insider ownership data.

Key Highlights

  • The derivative securities award left Aslan Fred with 155,000 derivative securities.
  • The 45,000-share award represented about 3.0% of Fred’s resulting share holding.
  • Both transactions carried SEC transaction code A.

Aslan Fred was awarded 45,000 shares of Artiva Biotherapeutics, Inc (NASDAQ: ARTV). on 10 September 2026. Fred is the company’s chief executive officer, and his reported share holding following the award was 1,494,765 shares.

Separate Share and Derivative Awards

A separate transaction awarded Fred 155,000 derivative securities on the same date. His resulting derivative securities holding was 155,000, and the award represented about 100.0% of that holding. The share award represented about 3.0% of his resulting shares. Both transactions were classified with SEC transaction code A. Transaction code A denotes an award, grant, or other Acquisition from the company.